DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Silvio Danese  ¹     Remo Panaccione  ²     Severine Vermeire  ³     David T. Rubin  ⁴     Dimpy Mehra  ⁵     Hsiuanlin Wu  ⁵     Mark T. Osterman  ⁵     HARRIS AHMAD  ⁵     Anjali Jain  ⁵     Maria T. Abreu  ^6    
1 Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
² Inflammatory Bowel Disease Clinic, Calgary, AB, Canada
³ University of Leuven, Leuven, Belgium
⁴ University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States
⁵ Bristol Myers Squibb, Princeton, United States
⁶ University of Miami Miller School of Medicine, Miami, United States

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)